OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bazhenova on a Correlative Analysis of the KRYSTAL-1 Trial in Advanced NSCLC

March 26th 2021

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma

March 26th 2021

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Dr. Bekaii-Saab on the Challenges of Utilizing Chemotherapy-Free Regimens in CRC

March 25th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Dr. del Rio on the Reactogenicity of the COVID-19 Vaccines

March 24th 2021

Carlos del Rio, MD, discusses the reactogenicity of the COVID-19 vaccines.

Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer

March 24th 2021

Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.

Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

March 24th 2021

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Dr. Usmani on Future Research Directions for Nirogacestat/Teclistamab in Myeloma

March 23rd 2021

Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.

Dr. Kamat on the Process of Meeting BCG Needs in Bladder Cancer

March 23rd 2021

Ashish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.

Dr. Ip on Remaining Questions With the COVID-19 Vaccine in Oncology

March 23rd 2021

Andrew Ip, MD, MS, discusses remaining questions with the COVID-19 vaccine in patients with cancer.

Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC

March 23rd 2021

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Choti on Challenging Treatment Decisions in NETs

March 23rd 2021

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

Dr. Basu-Mallick on the Importance of Clinical Research Examining ctDNA in CRC

March 22nd 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

March 22nd 2021

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

Dr. Davies on the Potential Role of Novel BRAF Inhibitors in Melanoma Brain Metastases

March 22nd 2021

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

Dr. Dorff on the Importance of Somatic Testing in mCRPC

March 22nd 2021

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

March 19th 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.